Skip to main content

Insulet Corporation company profile

  • PODD · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$152.48+2.14%Close 13 Nov 2026 · Market value $10.12B

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod platform includes Omnipod 5, Omnipod DASH, and the Classic Omnipod, a tubeless, self-adhesive disposable Pod controlled by a handheld device or a smartphone app. The company also produces pods for Amgen's Neulasta Onpro kit. In the United States, it sells primarily through wholesalers, with additional sales to healthcare organizations, pharmacies, and consumers. Internationally, it sells directly to consumers or through distributors and intermediaries. Manufacturing is conducted at facilities in Acton, Massachusetts, and Johor, Malaysia, with a contract manufacturing facility in China.

A summary of the business section of the company's latest annual report, filed 18 Feb 2026.

Company facts

TickerPODD · Nasdaq
SectorMedical devices
IndustryHealth Care Equipment
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK1145197
Latest annual report10-K, filed 18 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
James HollingsheadFormer President and CEO43.1K · < 1%Shares withheld for tax, 28 Apr 2025
John KapplesSVP and General Counsel40.5K · < 1%Shares withheld for tax, 27 Feb 2026
Eric BenjaminEVP and COO36.1K · < 1%Shares withheld for tax, 27 Feb 2026
Timothy J. ScannellDirector31.4K · < 1%Grant or award, 20 May 2026
Jessica HopfieldDirector31.3K · < 1%Grant or award, 20 May 2026
Michael R. MinogueDirector22.5K · < 1%Grant or award, 20 May 2026
Ashley A. McEvoyPresident and CEO · Director13.6K · < 1%Open-market purchase, 21 Aug 2026
Mark FieldSVP & Chief Technology Officer7.0K · < 1%Shares withheld for tax, 28 Feb 2025
Prem SinghSVP, Global Operations5.8K · < 1%Shares withheld for tax, 27 Feb 2026
Elizabeth H. WeathermanDirector5.2K · < 1%Open-market purchase, 3 Jun 2026
Ana ChadwickEVP, CFO & Treasurer4.6K · < 1%Shares withheld for tax, 1 May 2025
Timothy C. StonesiferDirector4.2K · < 1%Open-market purchase, 3 Jun 2026
Luciana BorioDirector3.1K · < 1%Open-market sale, 3 Jun 2026
Wayne A. I. FrederickDirector1.2K · < 1%Grant or award, 20 May 2026
Flavia H. PeaseEVP &amp; CFO543 · < 1%Shares withheld for tax, 1 Oct 2026
Robert L. HuffinesDirector106 · < 1%Grant or award, 30 Sep 2026
MAZELSKY JONATHAN JAYDirector—Grant or award, 30 Sep 2026
Davis Lisa BlairSVP, Chief HR Officer—Shares withheld for tax, 1 Aug 2026
Panos MichaelEVP and CCO—Grant or award, 1 Apr 2026
Cousin LaetitiaSVP, Reg, Quality & Compliance—Shares withheld for tax, 27 Feb 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

PODD in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.